A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations

Vaccine

Volumn 24, Issue 21, 2006, Pages 4494-4497

  Hinkula, Jorma ^a,b   Devito, Claudia ^a   Zuber, Bartek ^a   Benthin, Reinhold ^a   Ferreira, Denise ^b   Wahren, Britta ^a,b   Schröder, Ulf ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Eurocine AB   (Sweden)

Author keywords

HIV 1 DNA adjuvant; Neutralizing antibodies

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; PLASMID DNA; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

ANIMALS; DNA, VIRAL; FECES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV ENVELOPE PROTEIN GP41; HIV-1; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; PEPTIDES; VACCINES, DNA; VAGINA;

EID: 33646846846     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.015     Document Type: Article

References (19)

1. Pope M., and Haase A.T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9 (2003) 847-852
2. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehuni S., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6 (2000) 200-206
3. Devito C., Hinkula J., Kaul R., Kimani J., Kiama P., Lopalco L., et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1 exposed, persistently seronegative subjects. J AIDS 30 (2002) 413-420
4. Lizeng O., Nilsson C., Sourial S., Andersson S., Larsen O., Aaby P., et al. Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2 exposed IgG seronegative individuals. J Virol 78 (2004) 7016-7022
5. Ljungberg K., Rollman E., Eriksson L., Hinkula J., and Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 302 (2002) 44-57
6. Rollman E., Hinkula J., Arteaga J., Zuber B., Kjerrstrom A., Liu M., et al. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther 11 (2004) 1146-1154
7. Hinkula J., Rollman E., Lundholm P., Benthin R., Okuda K., and Wahren B. Genetic immunization with multiple HIV genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo. Cells Tissues Organs 177 (2004) 169-184
8. Jounai N., Okuda K., Kojima V., Hamaijma K., Ohba K., Klinman D., et al. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV. J Gene Med 5 (2003) 609-617
9. Matoba N., Magreus A., Geyer B.C., Zhang Y., Muralidharan M., Alfsen A., et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci USA 37 (2004) 13584-13589
10. Schröder U., and Svenson S.B. Nasal and parenteral immunizations with diphteria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Vaccine 17 (1999) 2096
11. Devito C., Zuber B., Schröder U., Benthin R., Okuda K., Broliden K., et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 173 (2004) 7078-7089
12. VanCott T.C., Kaminski R.W., Mascola J.R., Kalyanaraman V.S., Wassef N.M., Alving C.R., et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 160 (1998) 2000
13. Asakura Y., Hinkula J., Leandersson A.-C., Fukushima J., Okuda K., and Wahren B. Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand J Immunol 46 (1997) 326-330
14. Asakura Y., Lundholm P., Kjerrström A., Benthin R., Lucht E., Fukushima J., et al. DNA-plasmids of HIV-1 induce systemic and mucosal immune responses. Biol Chem 380 (1999) 375-379
15. Lundholm P., Asakura Y., Hinkula J., Lucht E., and Wahren B. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine 17 (1999) 2036-2042
16. Rowcliffe E., Bolmstedt A., Biller M., Wahren B., Olofsson S., and Hinkula J. Demonstration of neutralizing mucosal IgA response to intranasal HIV-1 env DNA vaccines with or without the V3 glycosylation site. Scand J Infect Dis 36 (2004) 360-364
17. Corbet S., Vinner L., Hougaard D.M., Bryder K., Nielsen C., and Fomsgaard A. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on primary, CCR5 tropic early HIV-1 type isolate (BX08) with human codons. AIDS Res Hum Retroviruses 10 (2000) 1997-2008
18. Shattock R.J., and Moore J.P. Inhibiting sexual transmission of HIV-1 infection. Nat Rev 1 (2003) 25-34
19. Mascola J., Stiegler R., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6 (2000) 207-210